How much funding has XDemics raised?

XDemics has disclosed $14.8M raised across 3 rounds.

Where is XDemics headquartered?

XDemics is headquartered in Novato, US.

XDemics

Novato, US · Delaware corporation

Find your way into XDemics

Each arrow is one introduction. Sign up to fill in the first one.

173 people can intro you to Christopher

Ask Sophia Lai to introduce you to Christopher Thanos

You →Sophia · together at Voro Therapeutics →Christopher

Your email: who you already know at XDemics, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the XDemics team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

XDemics develops cell culture and biomanufacturing technologies for generating mammalian cells at high densities for advanced therapy production. The company's HDCR platform and related products enable researchers and GMP facilities to produce T cell, stem cell, and viral-based therapies with improved quality and consistency.

Biotech Deep Tech Hardware Healthtech Medical Devices

Founders & leadership

Christopher Thanos Chairman and CEOChristopher Thanos is Chairman and CEO of XDemics, a Caltech spinout developing cell culture and biomanufacturing technologies. With over 30 years in biotechnology R&D, he is a named inventor on 35 issued patents and has co-founded or contributed to multiple therapeutics companies including Voro Therapeutics, Actym Therapeutics, and Sutro Biopharma, with platform technologies now in clinical development across cell therapies, antibody-drug conjugates, and vaccines.

Board

Colin CookCo-founder and CTO

Nicole BergmanBoard director

Reported raises · per SEC filings

Form D private placements

$14.8M disclosed across 3 rounds · 2024–2025

▶$7.4MraisedFeb 2026 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Nicole BergmanDirector
Colin CookDirector
Christopher ThanosExecutive Officer, Director

Offering amount: $7.4M
Amount sold: $7.4M
First sale: Oct 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5.5MraisedDec 2024 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Nicole BergmanDirector
Colin CookDirector
Christopher ThanosExecutive Officer, Director

Offering amount: $7.6M
Amount sold: $5.5M
First sale: Nov 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.9MraisedSep 2024 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Colin CookDirector
Christopher ThanosExecutive Officer, Director
Nicole BergmanDirector

Offering amount: $1.9M
Amount sold: $1.9M
First sale: May 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

Molecular DevicesMolecular Devices provides automated systems and services to support 3D cell biology research workflows, including cell culture automation, organoid expansion services, and imaging analysis tools for drug discovery and preclinical research.

Companies working in the same space as XDemics.

Frequently asked questions

What does XDemics do?: XDemics develops cell culture and biomanufacturing technologies for generating mammalian cells at high densities for advanced therapy production. The company's HDCR platform and related products enable researchers and GMP facilities to produce T cell, stem cell, and viral-based therapies with improved quality and consistency.
How much funding has XDemics raised?: XDemics has disclosed $14.8M raised across 3 rounds.
Where is XDemics headquartered?: XDemics is headquartered in Novato, US.